Hi mate,
Concerning TimelinesI am not really focused on when the chewies will come to market.
I don't believe there is any urgency for chewies' trials. Let me explain why.
I am ranking our products/development pipelines in terms of attractiveness to a BUY-OUT.
Firstly, if you were a prospective purchaser of part of the IHL suite of products, which would be your first choice?
Would your decision-making process be based on how much the pipeline was derisked / safe as an investment?
If you had access to all the funds required to buy part of IHL, like you were the CEO of a Big Pharma Company, what would part would you find most attractive?
My order book for 2023-4 ( Based on the probability of success )
1. IHL-42X (most de-risked) success already with Phase 2 (Australian Trials) pending opening of a US FDA IND. (400 participants.)
What would I need to pay?
$2-$3 to IHL coffers per share?
The BOD would likely consider accepting the offer, pass on 2/3 by way of a Special Dividend to Shareholders then;
2. PSI-GAD would be the next cab off the rank (accept another $1-2-3 per share and pass on 2/3 to shareholders), remember the little subsidiary company set up for the psychedelics separation?
Following me on this de-risk & sale process strategy?
This strategy is not new! If we were like a small exploration company on the ASX and we did thousands of meters of drilling and had a proven resource (did the BFS - JORG and all that stuff), would/could it be an attractive buy for a BHP or RIO?
The BOD could consider selling off each part/pipeline as and when each had been sufficiently de-risked, to be attractive enough to receive top dollars from Big Pharma.
Now as I see it, once we get to some point down this path and we take a look in the rear vision mirror, I would ask, was the revenue from the Chewies that important in 2022?
Could we use the funds received from selling off the first one or two parts, (with several parts remaining for sale) to re-invest in the remaining pipelines to further de-risk them?
This is a real strategy!
This is a strategy that is in play with IHL currently.
We know the milestones are in place already with Robert Clark.
Let's support the BOD implement that strategy, with full knowledge that the BOD are "
shareholders building a business for its shareholders".
Maybe once the first one or two parts are sold between now and May 2024, then we can consider selling the further de-risked Chewies? (2025 onwards maybe?)
I think other posters have alluded to this strategy already, but sometimes the long view is clouded by short-term SP bumping considerations around seeking revenue to prop up our share price.
I think some of us can see the bigger plan in play here.
GLAH, have a lovely weekend
